Molecular screening for an underlying myeloproliferative neoplasm in patients with stroke: who and how? TO THE EDITOR: In a recent issue of Blood Research, Song and colleagues highlighted the number of patients with cerebral infarctions and either erythrocytosis or thrombocytosis in whom further investigation of a myeloproliferative neoplasm (MPN) was not sought [1] . Extrapolated globally, where the lifetime risk of stroke is approximately 25%, this seemingly small number of patients with an underlying MPN would represent a considerable proportion of worldwide stroke cases in which intervention with specific MPN-directed therapies, both established and novel, would be missed [2, 3] .
This important finding raises some considerations. In addition to improved communication between hematologists and neurologists, would the authors suggest implementation and justification of an MPN-associated molecular screening programme for all patients with stroke, regardless of the presence of an erythrocytosis or thrombocytosis? Furthermore, the vast majority of MPN patients presenting with stroke have molecular evidence of the JAK2 V617F mutation, however rare cases harboring JAK2 exon 12, MPL exon 10 and CALR exon 9 mutations have been reported [4] [5] [6] . Would the authors therefore consider incorporating these other MPN-associated driver mutations into any molecular screening programme? As MPN-directed therapy should be regarded as an integral component of secondary stroke prevention [7] , identification or exclusion of this underlying malignant cause should be a priority.
Stephen E. Langabeer Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland ). Based on these observations, they concluded that mutation screening was not warranted as part of the hypercoagulable work-up in the absence of MPN [1] . In addition, JAK2V617F seems to be found in normal population [2] .
Furthermore, currently early detection of MPN driver gene mutations does not confer therapeutic implications in stroke patients with normal hematologic features, because available hematologic intervention such as cytoreductive therapy is indicated only in patients with overt thrombocytosis or erythrocytosis. Accordingly, we need to pay more attention to hematologic alterations at the time of diagnosis and regular follow-up of hematologic tests in patients with stroke rather than routine molecular screening, at least in daily clinical practice. For the selected cases of embolic stoke or cerebrovascular sinus thrombosis with otherwise undetermined source, molecular screening for MPN may be reasonable even in the absence of abnormal hematologic findings [3] . Collectively, molecular screening for MPN in stoke patients is still an open question, requiring prospective investigations and discussions.
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